- Home
- VYNE vs RDI Comparison
VYNE vs RDI Comparison
Compare VYNE & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VYNE | RDI |
|---|---|---|
| Founded | 2003 | 1937 |
| Country | United States | United States |
| Employees | N/A | 2005 |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 23.4M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | VYNE | RDI |
|---|---|---|
| Price | $0.66 | $1.16 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 144.2K | 27.4K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $16.25 |
| Revenue Next Year | N/A | $4.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.94 |
| 52 Week High | $1.96 | $1.65 |
Technical Indicators
Market Signals| Indicator | VYNE | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 45.99 | 55.38 |
| Support Level | $0.56 | $0.99 |
| Resistance Level | $0.69 | $1.16 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 49.10 | 60.39 |
Price Performance
Historical ComparisonAbout VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.